Issues surrounding standardization of meningococcal group W135 serology

Paul Balmer, Raymond Borrow

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Group W135 polysaccharide vaccines were licensed without efficacy trials using the serum bactericidal antibody (SBA) assay as a surrogate of protection. Standardization of group A and C SBA assays has been largely achieved. However, no such efforts have been focussed on W135. Although W135 strains have been recommended by WHO for polysaccharide production, no such recommendation are in place for use in immunoassays. Strain characterization is of importance as W135 strains may possess either an O-acetylated or de-O-acetylated polysaccharide capsule and the human immune response can vary according to the O-acetylation of the target antigen. Following conjugate or polysaccharide vaccination, few data are published with respect to complement source comparisons although both human and baby rabbit sera have been utilized with similar end points. In studies of natural immunity subcapsular antigens are primarily the target antigens and thus strain choice for use in the SBA assay is important. International standardization of assays is necessary to allow for comparisons of data over time and place.

Original languageEnglish
Pages (from-to)A63-A68
JournalVaccine
Volume25
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 3 Sep 2007
Externally publishedYes

Keywords

  • Bactericidal
  • Group W135
  • Meningococcal
  • Vaccine

Fingerprint

Dive into the research topics of 'Issues surrounding standardization of meningococcal group W135 serology'. Together they form a unique fingerprint.

Cite this